19 148
[37]
Giberti C, Chiono L, Gallo F, Schenone M, Gastaldi E. Radical retropubic prostatectomy versus brachytherapy for low-risk pros- tatic cancer: a prospective study. World J Urol 2009;27:607–12.
[38]
Harden JK, Sanda MG, Wei JT, et al. Partners’ long-term appraisal of their caregiving experience, marital satisfaction, sexual satisfac- tion, and quality of life 2 years after prostate cancer treatment. Cancer Nurs 2013;36:104–13.
[39]
Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002;347:790–6.
[40]
Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfac- tion with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250–61.
[41]
Talcott JA, Manola J, Clark JA, et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol 2003;21:3979–86.[42]
Resnick MJ, Koyama T, Fan KH, et al. Long-term functional out- comes after treatment for localized prostate cancer. N Engl J Med 2013;368:436–45.
[43]
Barocas DA, Alvarez J, Resnick MJ, et al. Association between radiation therapy, surgery, or observation for localized prostate cancer and patient-reported outcomes after 3 years. JAMA 2017;317:1126–40.
[44]
Chen RC, Basak R, Meyer AM, et al. Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer. JAMA 2017;317: 1141–50.
[45]
Whiting PF, Moore TH, Jameson CM, et al. Symptomatic and quality-of-life outcomes after treatment for clinically localised prostate cancer: a systematic review. BJU Int 2016;118:193–204.
[46]
Martin NE, Massey L, Stowell C, et al. Defining a standard set of patient-centered outcomes for men with localized prostate can- cer. Eur Urol 2015;67:460–7.
[47]
Nam RK, Cheung P, Herschorn S, et al. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a pop- ulation-based cohort study. Lancet Oncol 2014;15:223–31.
[48]
Wallis CJ, Herschorn S, Saskin R, et al. Complications after radical prostatectomy or radiotherapy for prostate cancer: results of a population-based, propensity score-matched analysis. Urology 2015;85:621–8.
[49]
Wallis CJ, Mahar A, Cheung P, et al. New rates of interventions to manage complications of modern prostate cancer treatment in older men. Eur Urol 2016;69:933–41.
[50]
Wallis CJ, Mahar AL, Cheung P, et al. Hospitalizations to manage complications of modern prostate cancer treatment in older men. Urology 2016;96:142–7.
[51]
Williams SB, Duan Z, Chamie K, et al. Risk of hospitalisation after primary treatment for prostate cancer. BJU Int 2017;120: 48–55.
[52]
Sheaff M, Baithun S. Pathological effects of ionizing radiation. Diagn Histopathol 1997;4:106–15.
[53]
Mundy AR, Andrich DE. Posterior urethral complications of the treatment of prostate cancer. BJU Int 2012;110:304–25.
[54]
Bassett MR, Santiago-Lastra Y, Stoffel JT, et al. Urinary diversion for severe urinary adverse events of prostate radiation: results from a multi-institutional study. J Urol 2016;197:744–50.
[55]
Wallis CJD, Mahar AL, Choo R, et al. Secondary malignancies after radiotherapy for prostate cancer: systematic review and meta- analysis. BMJ 2016;352:i851.
[56]
Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol 2009;10:718–26.
[57]
Baxter NN, Habermann EB, Tepper JE, Durham SB, Virnig BA. Risk of pelvic fractures in older women following pelvic irradiation. JAMA 2005;294:2587–93.
[58]
Chan S, Rowbottom L, McDonald R, et al. Pelvic insufficiency fractures in women following radiation treatment: a case series. Ann Palliat Med 2016;5:233–7.
[59]
Wallis CJ, Mahar AL, Satkunasivam R, et al. Cardiovascular and skeletal-related events following localised prostate cancer treat- ment: role of surgery, radiotherapy and androgen-deprivation. Urology 2016;97:145–52.
[60]
Thorstenson A, Bratt O, Akre O, et al. Incidence of fractures causing hospitalisation in prostate cancer patients: results from the pop- ulation-based PCBaSe Sweden. Eur J Cancer 2012;48:1672–81.
[61]
Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010;11:1066–73.
[62]
Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long- term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285–90.
[63]
D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for pros- tate cancer: a randomized trial. JAMA 2008;299:289–95.
[64]
Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of andro- gen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:2516–27.
[65]
Pisansky TM, Hunt D, Gomella LG, et al. Duration of androgen suppression before radiotherapy for localized prostate cancer: Radiation Therapy Oncology Group randomized clinical trial 9910. J Clin Oncol 2015;33:332–9.
[66]
Rhee H, Gunter JH, Heathcote P, et al. Adverse effects of androgen- deprivation therapy in prostate cancer and their management. BJU Int 2015;115(Suppl 5):3–13.
[67]
Higano CS. Sexuality and intimacy after definitive treatment and subsequent androgen deprivation therapy for prostate cancer. J Clin Oncol 2012;30:3720–5.
[68]
Haliloglu A, Baltaci S, Yaman O. Penile length changes in men treated with androgen suppression plus radiation therapy for local or locally advanced prostate cancer. J Urol 2007;177:128–30.
[69]
Hadziselimovic F, Senn E, Bandhauer K. Effect of treatment with chronic gonadotropin releasing hormone agonist on human testis. J Urol 1987;138:1048–50.
[70]
Couper JW, Love AW, Dunai JV, et al. The psychological aftermath of prostate cancer treatment choices: a comparison of depression, anxiety and quality of life outcomes over the 12 months following diagnosis. Med J Austral 2009;190(7 Suppl):S86–9.
[71]
Zapatero A, Guerrero A, Maldonado X, et al. Late radiation and cardiovascular adverse effects after androgen deprivation and high-dose radiation therapy in prostate cancer: results from the DART 01/05 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2016;96:341–8.
[72]
Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011;306:2359–66.
[73]
Brassell SA, Elsamanoudi SI, Cullen J, Williams ME, McLeod DG. Health-related quality of life for men with prostate cancer—an evaluation of outcomes 12-24 months after treatment. Urol Oncol 2013;31:1504–10.
[74]
Adam M, Tennstedt P, Lanwehr D, et al. Functional outcomes and quality of life after radical prostatectomy only versus a combina- tion of prostatectomy with radiation and hormonal therapy. Eur Urol 2017;71:330–6.
[75]
Gay HA, Michalski JM, Hamstra DA, et al. Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multi- center prospective study. Urology 2013;82:1363–8.E U R O P E A N U R O L O G Y 7 3 ( 2 0 1 8 ) 1 1 – 2 0
19